These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24629489)

  • 1. KRAS mutational analysis in ductal adenocarcinoma of the pancreas and its clinical significance.
    Miglio U; Oldani A; Mezzapelle R; Veggiani C; Paganotti A; Garavoglia M; Boldorini R
    Pathol Res Pract; 2014 May; 210(5):307-11. PubMed ID: 24629489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes.
    Immervoll H; Hoem D; Kugarajh K; Steine SJ; Molven A
    Virchows Arch; 2006 Jun; 448(6):788-96. PubMed ID: 16598499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.
    Kojima K; Vickers SM; Adsay NV; Jhala NC; Kim HG; Schoeb TR; Grizzle WE; Klug CA
    Cancer Res; 2007 Sep; 67(17):8121-30. PubMed ID: 17804724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence.
    Amintas S; Fernandez B; Chauvet A; Chiche L; Laurent C; Belleannée G; Marty M; Buscail E; Dabernat S
    Sci Rep; 2022 Feb; 12(1):2976. PubMed ID: 35194118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis.
    Löhr M; Klöppel G; Maisonneuve P; Lowenfels AB; Lüttges J
    Neoplasia; 2005 Jan; 7(1):17-23. PubMed ID: 15720814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma.
    Choi MH; Mejlænder-Andersen E; Manueldas S; El Jellas K; Steine SJ; Tjensvoll K; Sætran HA; Knappskog S; Hoem D; Nordgård O; Hovland R; Molven A
    BMC Cancer; 2019 Jan; 19(1):11. PubMed ID: 30611220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
    Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
    J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
    Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
    Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
    Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
    Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In pancreatic ductal adenocarcinoma blood concentrations of some organochlorine compounds and coffee intake are independently associated with KRAS mutations.
    Porta M; López T; Pumarega J; Jariod M; Crous-Bou M; Marco E; Rifà J; Grimalt JO; Malats N; Real FX;
    Mutagenesis; 2009 Nov; 24(6):513-21. PubMed ID: 19797353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients.
    Guo S; Shi X; Shen J; Gao S; Wang H; Shen S; Pan Y; Li B; Xu X; Shao Z; Jin G
    Br J Cancer; 2020 Mar; 122(6):857-867. PubMed ID: 31969677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of KRAS Mutation in Acinar and Langerhans Islet Cells of Patients With Pancreatic Ductal Adenocarcinoma.
    Wang Z; Zhang C; Nagee K; Mohammadi A; Monteiro C
    Pancreas; 2016 Mar; 45(3):337-41. PubMed ID: 26474433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions.
    Nagawkar SS; Abu-Funni S; Simon E; Bick T; Prinz E; Sabo E; Ben-Izhak O; Hershkovitz D
    Pancreas; 2016 Jul; 45(6):876-81. PubMed ID: 26646269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.
    Baechmann S; Ormanns S; Haas M; Kruger S; Remold A; Modest DP; Kirchner T; Jung A; Werner J; Heinemann V; Boeck S
    BMC Cancer; 2017 May; 17(1):374. PubMed ID: 28549417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models.
    Shen R; Wang Q; Cheng S; Liu T; Jiang H; Zhu J; Wu Y; Wang L
    Cancer Lett; 2013 Oct; 339(1):135-43. PubMed ID: 23887057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma.
    Van den Broeck A; Sergeant G; Ectors N; Van Steenbergen W; Aerts R; Topal B
    Eur J Surg Oncol; 2009 Jun; 35(6):600-4. PubMed ID: 19131205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Implications of Multiplex Detection of
    Kim MK; Woo SM; Park B; Yoon KA; Kim YH; Joo J; Lee WJ; Han SS; Park SJ; Kong SY
    Clin Chem; 2018 Apr; 64(4):726-734. PubMed ID: 29352043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.